Pfizer Limited
Quality (82/100) does the heavy lifting; financial trend (16/100) is the drag.
Buy zoneStocksWizard rates Pfizer Limited a Hold, scoring 51/100 on our blended model. At ₹4,060.2 it trades below our blended DCF and relative-multiples fair value of ₹4,357.58, about 7% upside to that estimate — we read it as fairly valued. On 28.6x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. It's sitting close to its 52-week low of ₹4,060.2. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹6,246 implies about 54% upside across 4 analysts. It clears 7 of 13 investability checks, with durability 82, valuation 68 and momentum 19 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹3,486.07.
Analyst views
1-year price
EOD · 2026-09-1252-week range
-25.38% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold51Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 17.2%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 6%
- Fail: Earnings growing: -40%
- Pass: Net margin ≥ 10%: 28.7%
- Pass: Current ratio > 1.5: 6.06
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 19.14
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter67.0%
- Institutions17.0%
- Public & other16.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (28.7%).
- Financially solid — Altman Z 19.14.
Opportunities
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Pfizer Limited
Pfizer Limited manufactures, markets, trades, and distributes pharmaceutical products across India and international markets. Its portfolio spans multiple therapeutic areas including neurology, cardiovascular disease, haemophilia, oncology, vaccines, respiratory conditions, gynecology, urology, and gastrointestinal treatments, alongside vitamins, minerals, and nutrients. The company also provides anti-infectives services.
Pfizer Limited — frequently asked questions
Is Pfizer Limited a buy, hold or sell?
StocksWizard currently rates Pfizer Limited (PFIZER) a Hold, based on a blended score of 51/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Pfizer Limited's fair value?
Our blended DCF and relative-valuation model estimates Pfizer Limited's fair value at about ₹4,357.58, versus a current price of ₹4,060.2 — roughly 7% upside. On that basis the stock looks fairly valued.
Is Pfizer Limited financially healthy?
Pfizer Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Pfizer Limited's share price performed?
Pfizer Limited is down 9% over three months, and last traded at ₹4,060.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.